COLORECTAL CANCER IN 2014 Progress in defining first-line and maintenance therapies

被引：40

作者：

Hubbard, Joleen M. ^{[1
]}

Grothey, Axel ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 02期

关键词：

PLUS BEVACIZUMAB;

D O I：

10.1038/nrclinonc.2014.233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

引用

页码：73 / 74

页数：2

共 10 条

[1]

[Anonymous], ANN ONCOL S4

[2]

[Anonymous], 2014, ANN ONCOL

[3]

[Anonymous], ANN ONCOL S4

[4]

[Anonymous], J CLIN ONCOL S3

[5] Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). [J].

Arnold, Dirk ;

Graeven, Ullrich ;

Lerchenmuller, Christian A. ;

Killing, Brigitta ;

Depenbusch, Reinhard ;

Steffens, Claus-Christoph ;

Al-Batran, Salah-Eddin ;

Lange, Thoralf ;

Dietrich, Georg ;

Stoehimacher, Jan ;

Tannapfel, Andrea ;

Schmoll, Hans-Joachim ;

Reinacher-Schick, Anke ;

Hegewisch-Becker, Susanna .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[6] Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Grothey, Axel ;

Van Cutsem, Eric ;

Sobrero, Alberto ;

Siena, Salvatore ;

Falcone, Alfredo ;

Ychou, Marc ;

Humblet, Yves ;

Bouche, Olivier ;

Mineur, Laurent ;

Barone, Carlo ;

Adenis, Antoine ;

Tabernero, Josep ;

Yoshino, Takayuki ;

Lenz, Heinz-Josef ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Cihon, Frank ;

Cupit, Lisa ;

Wagner, Andrea ;

Laurent, Dirk .

LANCET, 2013, 381 (9863) :303-312

[7] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].

Heinemann, Volker ;

von Weikersthal, Ludwig Fischer ;

Decker, Thomas ;

Kiani, Alexander ;

Vehling-Kaiser, Ursula ;

Al-Batran, Salah-Eddin ;

Heintges, Tobias ;

Lerchenmueller, Christian ;

Kahl, Christoph ;

Seipelt, Gernot ;

Kullmann, Frank ;

Stauch, Martina ;

Scheithauer, Werner ;

Hielscher, Joerg ;

Scholz, Michael ;

Mueller, Sebastian ;

Link, Hartmut ;

Niederle, Norbert ;

Rost, Andreas ;

Hoeffkes, Heinz-Gert ;

Moehler, Markus ;

Lindig, Reinhard U. ;

Modest, Dominik P. ;

Rossius, Lisa ;

Kirchner, Thomas ;

Jung, Andreas ;

Stintzing, Sebastian .

LANCET ONCOLOGY, 2014, 15 (10) :1065-1075

[8] INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION [J].

Stintzing, S. ;

Modest, D. P. ;

von Weikersthal, L. Fischer ;

Decker, T. ;

Kiani, A. ;

Vehling-Kaiser, U. ;

Al-Batran, S. ;

Heintges, T. ;

Lerchenmueller, C. ;

Kahl, C. ;

Seipelt, G. ;

Kullmann, F. ;

Scheithauer, W. ;

Held, S. ;

Giessen, C. ;

Moehler, M. ;

Jagenburg, A. ;

Jung, A. ;

Kirchner, T. ;

Heinemann, V. .

ANNALS OF ONCOLOGY, 2014, 25

[9]

Van Cutsem E., 2014, ANN ONCOL, V25, pv1

[10]

Venook AP, 2014, J CLIN ONCOL S, V32

← 1 →